{"id":"https://openalex.org/W4390201513","doi":"https://doi.org/10.1002/alz.076948","title":"AZP2006, a New Promising Treatment for Progressive Supranuclear Palsy patients. Phase 2a Study Assessing Tolerability, Safety and Pharmacokinetics. Effect on Biomarkers and Clinical Readouts","display_name":"AZP2006, a New Promising Treatment for Progressive Supranuclear Palsy patients. Phase 2a Study Assessing Tolerability, Safety and Pharmacokinetics. Effect on Biomarkers and Clinical Readouts","publication_year":2023,"publication_date":"2023-12-01","ids":{"openalex":"https://openalex.org/W4390201513","doi":"https://doi.org/10.1002/alz.076948"},"language":"en","primary_location":{"id":"doi:10.1002/alz.076948","doi":"https://doi.org/10.1002/alz.076948","is_oa":true,"landing_page_url":"https://doi.org/10.1002/alz.076948","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.076948","source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.076948","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014873420","display_name":"Philippe Verwaerde","orcid":"https://orcid.org/0000-0002-0184-1990","observed_orcids":["https://orcid.org/0000-0002-0184-1990"]},"institutions":[{"id":"https://openalex.org/I4405265732","display_name":"Alzprotect (France)","ror":"https://ror.org/05kk7gg34","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405265732"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Philippe Verwaerde","raw_affiliation_strings":["Alzprotect, Loos, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzprotect, Loos, France","institution_ids":["https://openalex.org/I4405265732"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017285757","display_name":"Cecilia Estrella","orcid":"https://orcid.org/0000-0002-8632-3083","observed_orcids":["https://orcid.org/0000-0002-8632-3083"]},"institutions":[{"id":"https://openalex.org/I4405265732","display_name":"Alzprotect (France)","ror":"https://ror.org/05kk7gg34","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405265732"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Cecilia Estrella","raw_affiliation_strings":["Alzprotect, Loos, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzprotect, Loos, France","institution_ids":["https://openalex.org/I4405265732"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068765891","display_name":"Aur\u00e9lien Blondel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265732","display_name":"Alzprotect (France)","ror":"https://ror.org/05kk7gg34","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405265732"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Aur\u00e9lien Blondel","raw_affiliation_strings":["Alzprotect, Loos, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzprotect, Loos, France","institution_ids":["https://openalex.org/I4405265732"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091292742","display_name":"Susanna Del Signore","orcid":"https://orcid.org/0000-0002-1270-326X","observed_orcids":["https://orcid.org/0000-0002-1270-326X"]},"institutions":[{"id":"https://openalex.org/I4405265732","display_name":"Alzprotect (France)","ror":"https://ror.org/05kk7gg34","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405265732"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Susanna Del Signore","raw_affiliation_strings":["Alzprotect, Loos, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzprotect, Loos, France","institution_ids":["https://openalex.org/I4405265732"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5061334483","display_name":"No\u00eblle Callizot","orcid":"https://orcid.org/0000-0002-4796-1592","observed_orcids":["https://orcid.org/0000-0002-4796-1592"]},"institutions":[{"id":"https://openalex.org/I4405265732","display_name":"Alzprotect (France)","ror":"https://ror.org/05kk7gg34","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405265732"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Noelle Callizot","raw_affiliation_strings":["Alzprotect, Loos, France","Neuro-Sys, Gardanne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzprotect, Loos, France","institution_ids":["https://openalex.org/I4405265732"]},{"raw_affiliation_string":"Neuro-Sys, Gardanne, France","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5014873420"],"corresponding_institution_ids":["https://openalex.org/I4405265732"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"19","issue":"S21","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.8964999914169312,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.8964999914169312,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.051899999380111694,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10855","display_name":"Amyotrophic Lateral Sclerosis Research","score":0.03790000081062317,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/progressive-supranuclear-palsy","display_name":"progressive supranuclear palsy","score":0.9959999918937683}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8745017051696777},{"id":"https://openalex.org/C2776477761","wikidata":"https://www.wikidata.org/wiki/Q945930","display_name":"Progressive supranuclear palsy","level":3,"score":0.8156793713569641},{"id":"https://openalex.org/C87753298","wikidata":"https://www.wikidata.org/wiki/Q17157137","display_name":"Neuroinflammation","level":3,"score":0.7129398584365845},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7072311639785767},{"id":"https://openalex.org/C2777739294","wikidata":"https://www.wikidata.org/wiki/Q2397106","display_name":"Tauopathy","level":4,"score":0.6926267743110657},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.560967743396759},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.551542341709137},{"id":"https://openalex.org/C2776925932","wikidata":"https://www.wikidata.org/wiki/Q1755122","display_name":"Neurodegeneration","level":3,"score":0.5210356712341309},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5188971161842346},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.46590501070022583},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4196528196334839},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41209548711776733},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.34340518712997437},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.294156938791275},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.2623945474624634},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/alz.076948","doi":"https://doi.org/10.1002/alz.076948","is_oa":true,"landing_page_url":"https://doi.org/10.1002/alz.076948","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.076948","source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1002/alz.076948","doi":"https://doi.org/10.1002/alz.076948","is_oa":true,"landing_page_url":"https://doi.org/10.1002/alz.076948","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.076948","source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4390201513.pdf","grobid_xml":"https://content.openalex.org/works/W4390201513.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4393870550","https://openalex.org/W4414570945","https://openalex.org/W4392190836","https://openalex.org/W4390199902","https://openalex.org/W2808257628","https://openalex.org/W2402539097","https://openalex.org/W2980879757","https://openalex.org/W2884078076","https://openalex.org/W2946761884","https://openalex.org/W3133453048"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Progressive":[2],"Supranuclear":[3],"Palsy":[4],"(PSP)":[5],"is":[6,17,279,320],"a":[7,18,88,108,244,288,307],"rare":[8],"progressive,":[9],"fatal":[10],"neurodegenerative":[11],"4\u2010repeat":[12],"tauopathy.":[13],"AZP2006":[14,52,83,93,119,223,239,254,282,316],"(INN:":[15],"Ezeprogind)":[16],"first\u2010in\u2010class":[19],"disease\u2010modifying":[20],"oral":[21],"small":[22],"molecule":[23],"acting":[24],"via":[25],"its":[26],"strong":[27],"binding":[28],"to":[29,38],"the":[30,40,125,180,237,262],"complex":[31],"Progranulin":[32],"(PGRN)":[33],"/":[34],"Prosaposin":[35],"(PSAP),":[36],"able":[37],"increase":[39,269],"circulating":[41],"contents":[42],"of":[43,70,118,185,194,272],"PGRN":[44,178,273],"(plasma":[45],"and":[46,61,66,74,96,103,129,148,153,183,217,226,253],"brain)":[47],"in":[48,67,99,107,145,243,303,312],"non\u2010clinical":[49],"models.":[50],"Preclinically,":[51],"promotes":[53],"neuron":[54],"survival,":[55],"synaptic":[56],"function,":[57],"decreases":[58],"Tau":[59],"hyperphosphorylation":[60],"reduces":[62],"neuroinflammation":[63,195],"(in":[64],"vitro":[65],"vivo":[68],"models":[69],"Alzheimer\u2019s":[71],"disease,":[72],"PSP":[73,211,213,313],"Parkinson\u2019s":[75],"disease).":[76],"In":[77,172,201,260,305],"healthy":[78],"volunteers":[79],"Phase":[80,309],"1":[81],"studies,":[82],"was":[84,224,251,265,298],"well":[85,191,227],"tolerated":[86],"with":[87,143,157],"good":[89],"safety":[90],"profile.":[91],"Method":[92],"safety,":[94],"tolerability":[95],"pharmacokinetic":[97],"profiles":[98],"plasma,":[100],"whole":[101],"blood,":[102],"CSF":[104,175,255],"were":[105,163,199,220,232,258],"investigated":[106],"randomized,":[109],"double\u2010blind,":[110],"placebo\u2010controlled,":[111],"parallel":[112],"group":[113],"study":[114,311],"comparing":[115],"2":[116],"doses":[117],"(60":[120,300],"mg":[121,131,140,301],"once":[122,132,141],"daily":[123,133],"during":[124],"12\u2010week":[126,168],"treatment":[127,283],"period":[128,170],"80":[130],"for":[134,165,179],"10":[135],"days":[136],"followed":[137],"by":[138,267],"50":[139],"daily)":[142,302],"placebo":[144],"36":[146],"men":[147],"women":[149],"aged":[150],"\u226540":[151],"years":[152,155],"\u226480":[154],"diagnosed":[156],"probable":[158],"or":[159],"possible":[160],"PSP.":[161],"Patients":[162],"observed":[164,252],"an":[166,294],"additional":[167],"follow\u2010up":[169],"(NCT04008355).":[171],"secondary":[173],"objectives,":[174],"biomarkers":[176],"including":[177],"target":[181,263],"engagement":[182,264],"markers":[184,193],"neurodegeneration":[186],"(NfL,":[187],"phospho\u2010tau":[188],"T181)":[189],"as":[190,192],"(sTREM2,":[196],"interleukins,":[197],"etc.)":[198],"quantified.":[200],"addition,":[202,261,306],"exploratory":[203],"efficacy":[204,317],"objectives":[205],"evaluating":[206],"clinical":[207],"endpoints":[208],"(PSP\u2010RS":[209],"total,":[210],"Gait,":[212],"Ocular,":[214],"CGI\u2010ds,":[215],"Schwab":[216],"England":[218],"ADL)":[219],"investigated.":[221],"Result":[222],"safe":[225],"tolerated;":[228],"no":[229],"related":[230],"SAEs":[231],"reported.":[233],"PK":[234],"profile":[235],"confirmed":[236,266],"long":[238],"half\u2010life":[240],"(as":[241],"predicted":[242],"prior":[245],"popPK":[246],"model).":[247],"High":[248],"brain":[249],"penetrance":[250],"expected":[256],"levels":[257],"achieved.":[259],"significant":[268],"(vs":[270],"baseline)":[271],"plasma":[274],"levels.":[275],"A":[276],"PD\u2010PK":[277],"analysis":[278],"planned.":[280],"Conclusion":[281],"showed":[284],"promising":[285,292],"effects":[286],"after":[287],"3\u2010month\u2010treatment.":[289],"Considering":[290],"these":[291],"results,":[293],"open\u2010labelled":[295],"extension":[296],"(OLE)":[297],"started":[299],"France.":[304],"larger":[308],"2b/3":[310],"patients":[314],"testing":[315],"over":[318],"12\u2010month\u2010treatment":[319],"under":[321],"preparation.":[322]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-12-26T00:00:00"}